Cervical cancer remains one of the most formidable public health challenges facing women in India, where screening coverage has historically hovered at dismally low levels despite the disease being largely preventable. A new district-level implementation study published in BMC Public Health offers a detailed blueprint for how the country’s public health system might finally close that gap. The research, conducted in Amethi district in the northern state of Uttar Pradesh, demonstrates that human papillomavirus (HPV) DNA testing—delivered through a combination of self-sampling, frontline health workers, and a hybrid of centralized and near point-of-care laboratory platforms—can be integrated into routine government services at scale. The findings arrive at a critical moment, because the World Health Organization has endorsed HPV DNA testing as the preferred modality for cervical cancer screening, yet its adoption within India’s sprawling and resource-constrained public infrastructure has remained limited, particularly in rural communities where the burden of disease is heaviest.
The study team, led by researchers from Dr. Ram Manohar Lohia Institute of Medical Sciences in Lucknow, the global health organization Jhpiego, and the Kalyan Singh Super Speciality Cancer Institute, designed the intervention to answer a pragmatic question: can WHO-recommended HPV DNA screening actually function within the existing machinery of a rural Indian district, rather than in a purpose-built research clinic? To find out, they leveraged the government’s own assets—its network of Health and Wellness Centres, its digital health platforms, and, crucially, its cadre of Accredited Social Health Activists, or ASHAs, the community health workers who serve as the connective tissue between villages and the formal health system. Women aged 30 to 65 years were identified as the eligible screening population, reflecting the age band in which cervical cancer risk is most concentrated and in which screening yields the greatest benefit.
The scale of the mobilization effort was considerable. Of 23,972 eligible women identified across the district, 10,141 ultimately underwent HPV DNA testing, corresponding to a screening uptake of 42 percent. That figure takes on greater significance when set against the baseline: in the intervention areas, screening coverage had previously stood at a mere 1.5 percent. By the end of the project period, coverage had climbed to more than 45 percent, a roughly thirtyfold increase achieved without constructing new facilities or importing an entirely parallel health delivery structure. The engine of this transformation, according to the study, was the offer of choice in how samples were collected. Women could either collect their own vaginal samples—a method that requires no pelvic examination and can be performed in the privacy of the home—or have a sample collected by a provider at a Health and Wellness Centre. The preference was striking: 83 percent of screened women opted for self-sampling, underscoring how profoundly the logistics of sample collection shape participation in screening programs.
The technical architecture of the testing pipeline is where the study makes some of its most useful contributions. Rather than committing to a single technology, the project deliberately evaluated two complementary platforms. High-throughput centralized laboratories could process large volumes of samples with the efficiency and quality control that molecular diagnostics at scale demand, while low-throughput near point-of-care devices brought testing closer to the communities where women live, shortening the distance between sample collection and result. HPV positivity across the different technology platforms fell within a narrow band of 3.3 to 4.7 percent, a consistency that matters enormously for program planners. It suggests that the choice of platform need not fundamentally alter the epidemiological picture a screening program generates, giving districts flexibility to match testing technology to local infrastructure, sample volumes, and supply chains rather than forcing a one-size-fits-all solution.
Genotype analysis added another layer of programmatic intelligence. HPV-16 emerged as the most prevalent high-risk genotype, accounting for 31 percent of positive results. This finding aligns with global patterns, in which HPV-16 and HPV-18 together drive the majority of cervical cancer cases, and it carries implications for both vaccination policy and the design of partial-genotyping assays that can flag infections caused by the most oncogenic virus types for more urgent clinical attention. In a screening program, knowing the local genotype distribution helps calibrate triage protocols and informs expectations about how many women will need follow-up procedures after a positive screen.
A positive HPV test is not a diagnosis of cancer; it is a signal that requires triage to distinguish transient infections from lesions that warrant treatment. The Amethi project operationalized this critical second step using Visual Inspection with Acetic Acid, or VIA, a low-cost technique in which diluted acetic acid is applied to the cervix and precancerous tissue temporarily turns white, making it visible to a trained provider. Women whose triage confirmed treatable lesions could receive thermal ablation—a method that destroys abnormal tissue using a heated probe—at sub-district facilities, keeping care close to home. Those requiring more advanced procedures, such as loop electrosurgical excision procedure, or LEEP, were referred upward through the system. The decentralized model worked: 52 percent of screen-positive women received thermal ablation locally, and notably, this proportion held steady regardless of whether a woman’s screening sample had been processed on the high-throughput centralized platform or the low-throughput near point-of-care device. The equivalence across platforms suggests that the hybrid testing model did not create inequities in downstream care.
The study is candid about its most persistent challenge: loss to follow-up. Women who screened positive but felt entirely well—because HPV infections and their precancerous consequences are asymptomatic in their early, most treatable stages—were the group most likely to drop out of the care cascade. This is a well-documented vulnerability of all screening programs, but it is especially acute where the screened condition is silent and where returning to a facility carries costs in time, travel, and wages. The authors point to the program’s digital dashboards, which enabled real-time monitoring of screening and treatment indicators, as a tool for identifying where women were falling through the cracks. Such data systems, the study suggests, are not administrative luxuries but core components of a screening program’s clinical effectiveness, allowing supervisors to target follow-up efforts precisely where the cascade is leaking.
Ethical oversight for the project was provided by the Institutional Ethics Committee of Dr. Ram Manohar Lohia Institute of Medical Sciences, with an additional Non-Research Determination from Johns Hopkins University, and procedures were conducted in accordance with the Declaration of Helsinki. Women undergoing HPV screening gave verbal consent, while participants enrolled in interviews examining loss to follow-up provided written informed consent. The work was partially supported by Roche Diagnostics, which reviewed the manuscript but, according to the authors, had no role in study design, data collection, data analysis, interpretation of findings, or the decision to submit the manuscript for publication. The authors declare no competing interests.
The significance of the Amethi project extends well beyond a single district in Uttar Pradesh. India carries a disproportionate share of the global cervical cancer burden, and the WHO’s global strategy to eliminate cervical cancer as a public health problem depends heavily on whether large, high-burden countries can achieve high screening coverage. The conventional obstacles are well known: cytology-based screening requires laboratory infrastructure and repeated visits that many women cannot manage; visual inspection methods, while cheap, are operator-dependent and less sensitive. HPV DNA testing breaks this trade-off by offering high sensitivity with a single visit for sample collection, and self-sampling removes the most intimate barrier of all. What the Amethi study adds is proof that this combination can run on government rails—ASHA mobilization, Health and Wellness Centres, district laboratories, and digital monitoring—rather than requiring a parallel donor-funded system that would be impossible to sustain.
The authors frame their conclusions around feasibility, acceptability, and programmatic relevance, and each is supported by concrete numbers: a thirtyfold rise in coverage, an 83 percent preference for self-sampling, consistent HPV positivity across platforms, and half of screen-positive women treated locally. The remaining work is equally concrete—closing the follow-up gap for asymptomatic screen-positive women, and translating a district demonstration into state and national policy. For program designers across India and in other low-resource settings, the study offers a woman-centered, data-driven template: mobilize trusted community health workers, let women choose self-collection, run a hybrid of centralized and point-of-care testing matched to local capacity, triage and treat as close to home as safely possible, and monitor every step in real time. If the lessons of Amethi travel, the study may come to be seen as an early milestone in India’s path toward cervical cancer elimination.
Subject of Research: Implementation of HPV DNA test-based cervical cancer screening with self-sampling in rural Indian public health settings
Article Title: Facilitating HPV DNA test-based screening for cervical cancer in public health settings of India: learnings from the Amethi project
Article References: Husain, N., Bhamare, P., Qureshi, S., Kaur, N., Nawaz, A. S., Hegde, S. K. B., Singh, D., Tripathi, S., & Kumar, S. (2026). Facilitating HPV DNA test-based screening for cervical cancer in public health settings of India: learnings from the Amethi project. BMC Public Health. https://doi.org/10.1186/s12889-026-29409-3
Image Credits: AI Generated
DOI: 10.1186/s12889-026-29409-3
Keywords: cervical cancer, HPV DNA testing, self-sampling, screening coverage, India, Uttar Pradesh, ASHA health workers, point-of-care testing, thermal ablation, VIA triage, HPV-16, public health
Cite Scienmag News
APA
MLA
Chicago
Copy citation
Download RIS
Tags: ASHA health workerscervical cancercervical cancer prevention in low-resource settingscommunity-based cervical cancer prevention programs in IndiaHPV DNA self-sampling for cervical cancer screening in rural IndiaHPV DNA testingHPV-16HPV-based cervical cancer screening scale-upimplementation of HPV testing in public health systemsIndiainnovative cervical cancer screening strategies in Indiaintegration of point-of-care HPV testing in rural healthcareovercoming healthcare infrastructure challenges for HPV testingpoint-of-care testingPublic healthresource-constrained publicscreening coverageself-samplingthermal ablationuse of frontline health workers for HPV self-samplingUttar PradeshVIA triageWHO guidelines for cervical cancer screening in developing countries
